Implantable defibrillators is a battery-powered small device placed underneath chest or abdomen to keep track of patient's heart rate. Increase in palpitation is diagnosed by the device and the normal heart rhythm is restored. These devices play a vital role in preventing sudden cardiac arrest in patients who suffer from sustained ventricular tachycardia or atrial fibrillation. Therefore, ICDs constantly monitor the heart rhythm through electrodes and deliver treatments when abnormal heart rhythm is detected. The treatments through ICDs include pacing, cardioversion, and defibrillation to restore normal heart rhythm.

The implantable defibrillator market was valued at $6,006 million in 2015, and is projected to reach $8,449 million by 2022, growing at a CAGR of 4.9% from 2016 to 2022. This is attributed to the advancements in the technology such as introduction of quadripolar lead devices to improve device programming, extend battery life, and development of magnetic resonance imaging (MRI)-safe ICDs. In addition, rise in incidence of atrial fibrillation and high risk of sudden cardiac arrest (SCA) fuel the demand for implantable defibrillator devices. Furthermore, introduction of subcutaneous ICD technology in 2012 has revolutionized the treatment technology for cardiac rhythm management through these devices. Boston Scientific's S-ICDs was granted market clearance in 2012, which was the first commercially available S-ICDs system worldwide. S-ICDs are widely adopted, as they are implanted below the skin without the leads to be placed inside the heart. This fueled the demand for S-ICDs globally, thus driving the growth of the market. However, presence of alternative treatment and limited insurance coverage are projected to hamper the market growth.

The implantable defibrillator market is segmented based on product type and geography. On the basis of product type, the market is segmented into transvenous implantable cardioverter-defibrillator (T-ICDs), subcutaneous implantable cardioverter defibrillators (S-ICDS), and cardiac resynchronization therapy defibrillator (CRT-D). Geographically, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Argentina, Egypt, Israel, South Africa, and rest of LAMEA).

KEY BENEFITS

This report provides an extensive analysis of the current & emerging market trends and dynamics in the global implantable defibrillator market.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
This report entails the detailed quantitative analysis of the current trends and future estimations to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Region- and country-wise market conditions are analyzed in the report.

KEY MARKET SEGMENTS

By Product Type

Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS)
Transvenous Implantable Cardioverter-Defibrillator (T-ICDs)
Cardiac Resynchronization Therapy Defibrillator (CRT-D)

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Rest of Asia-Pacific
LAMEA
Brazil
Argentina
Egypt
Israel
South Africa
Rest of LAMEA

KEY PLAYERS

Boston Scientific Corporation
LivaNova PLC Company
Imricor Medical Systems
MicroPort Scientific Corporation
Mayo Clinic US
Medtronic Plc
MRI Interventions, Inc.
St. Jude Medical, Inc.
Biotronik Se & Co.KG
Sorin Group